DVL Stock Overview
Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for DVL from our risk checks.
Alliance Pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.39 |
| 52 Week High | UK£0.82 |
| 52 Week Low | UK£0.36 |
| Beta | 0.58 |
| 1 Month Change | -10.45% |
| 3 Month Change | -7.51% |
| 1 Year Change | -38.91% |
| 3 Year Change | -63.85% |
| 5 Year Change | -55.07% |
| Change since IPO | -64.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| DVL | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.4% | 2.5% | 1.8% |
| 1Y | -38.9% | -27.7% | 2.2% |
Return vs Industry: DVL underperformed the German Pharmaceuticals industry which returned -31.9% over the past year.
Return vs Market: DVL underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| DVL volatility | |
|---|---|
| DVL Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DVL's share price has been volatile over the past 3 months.
Volatility Over Time: DVL's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 285 | Andrew Franklin | www.alliancepharmaceuticals.com |
Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. The company also offers medicines, medical devices, food supplements, and cosmetics.
Alliance Pharma plc Fundamentals Summary
| DVL fundamental statistics | |
|---|---|
| Market cap | €223.12m |
| Earnings (TTM) | -€8.21m |
| Revenue (TTM) | €197.77m |
1.1x
P/S Ratio-27.2x
P/E RatioIs DVL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DVL income statement (TTM) | |
|---|---|
| Revenue | UK£170.05m |
| Cost of Revenue | UK£72.14m |
| Gross Profit | UK£97.91m |
| Other Expenses | UK£104.97m |
| Earnings | -UK£7.06m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | 57.58% |
| Net Profit Margin | -4.15% |
| Debt/Equity Ratio | 43.6% |
How did DVL perform over the long term?
See historical performance and comparison